Please assess the completion status of the following clinical trial:

Trial Title: Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female attendees (age ≥18yo) of the Ubuntu HIV and ARV Clinic identified as eligible for the ARV programme will be invited to participate.~2. Willingness to participate~3. Able to engage in informed consent procedures~Exclusion Criteria:~1. Evidence of active TB or suspicion of active TB as determined by a symptoms screening algorithm.~2. Current TB chemotherapy ( TB treatment completed in the preceding 30 days will not be an exclusion)~3. Current or previous treatment of latent TB infection since HIV infection (any duration)~4. Current treatment with fluoroquinolones or other antibiotics with significant anti-tuberculous activity currently being used to treat TB in South Africa~5. Past reaction/intolerance to INH.~6. Acute hepatitis or existing Grade III-IV peripheral neuropathy.~7. Pregnancy or \< 6weeks post-partum period (Due to increased risk of hepatotoxicity).~8. Grade III or higher baseline abnormal liver function. (Note: toxicity grades are all according to ACTG toxicity tables for persons on ART).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.Isoniazid (INH) (Type: EXPERIMENTAL): A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
- 2. Placebo (Type: PLACEBO_COMPARATOR): A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).